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Abstract 
Hyponatremia is a common complication in neonatal polycystic kidney disease and is thought 
to be due to water retention. Aquaretics are drugs that promote free water excretion by blocking 
the arginine vasopressine receptor type 2 (AVPR2) in the collecting duct and thus impair 
urinary concentration. AVPR2 is also a key stimulant for cyclic AMP production in the 
collecting duct and in this way promotes cyst proliferation and pathologic kidney growth in 
autosomal dominant polycystic kidney disease (ADPKD). Consequently, the aquaretic 
tolvaptan is now used to slow down progression of ADPKD in adult patients. Whether this 
beneficial effect on retarding cystic disease progression also extends to recessive forms of 
polycystic kidney disease (PKD) is currently not known. A case report in this edition of 
Pediatric Nephrology touches on the intersecting indications for tolvaptan for both 
hyponatremia and cyst retardation in neonatal PKD and suggests that use for one indication 
may have beneficial effects on the other. 
 
Key words: aquaretic, tolvaptan, ADPKD, ARPKD, hyponatremia  
Aquaretics and hyponatremia 
With the discovery of the arginine vasopressin receptor type 2 receptor (AVPR2) in the kidney 
and its dysfunction as the cause of X-linked nephrogenic diabetes insipidus (NDI), AVPR2 
immediately became an attractive target for drug development. Since then, the highly specific 
agonist 1-deamino-8-D-arginine vasopressin (DDAVP) has become available and is routinely 
used in the treatment of cranial NDI. More recently, antagonists have been developed, the so-
called “aquaretics” or “vaptans”, which are used in conditions of water excess, such as the 
syndrome of inappropriate antidiuretic hormone (SIADH) or congestive heart failure [1]. The 
development of these drugs beautifully demonstrates how the study of a rare disease (X-linked 
NDI, which identified the drug target) can benefit other, more common diseases. 
 
Aquaretics and polycystic kidney disease 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause 
of kidney failure, accounting for up to 10% of end stage kidney disease in adults [2]. 
Investigations into the molecular mechanisms of ADPKD identified cyclic AMP (cAMP) as a 
key driver for cyst and pathologic kidney growth and AVPR2 as the main stimulant for cAMP 
production in the collecting duct [3]. Consequently, aquaretics became an attractive drug for 
the treatment of ADPKD and a large trial indeed showed that the treatment slowed cyst and 
kidney growth [4]. Based on these data, in some parts of the world, including the UK, tolvaptan 
has been approved as the first medical treatment of ADPKD in adults. A trial to investigate the 
effect in children is currently underway. Tolvaptan comes at a price: not only is there a risk of 
liver toxicity, but there is quite literally a price to pay: we recently calculated that a year’s 
treatment of hyponatremia in the UK with one 15 mg tablet daily cost more than £30.000 [5]. 
To facilitate the long-term treatment of ADPKD, the company has lowered the price for the 
ADPKD indication. This has led to the somewhat bizarre situation that tolvaptan is currently 
marketed by the same company under two different brand names and with two different price 
tags: as the more expensive SAMSCA for the treatment of hyponatremia and as JINARC 
for ADPKD.  
 
Aquaretics in the treatment of hyponatremia as a complication of PKD 
A case report in this edition of Pediatric Nephrology straddles the indications for the two brands 
and raises some interesting questions: Olalekan et al report a case of an infant with biallelic 
PKD1 variants who was treated with tolvaptan [6]. In rare instances, like the reported case, the 
combination of a disease-causing ADPKD mutation on one allele with a hypomorphic variant 
on the other allele can cause a form of severe neonatal PKD that is mimicking the autosomal 
recessive form (ARPKD) [7]. Renal abnormalities in this baby were already noted antenatally 
at 17-week gestation in the form of large, echobright kidneys and she was born with massively 
enlarged kidneys. During the first months of life she developed typical complications of severe 
neonatal PKD, including hyponatremia, hypertension, edema and respiratory distress. The 
hyponatremia creates a management dilemma: How best to treat? Supplementation with 
sodium to normalize plasma sodium levels usually worsens the hypertension. Clinically, the 
combination of hyponatremia and hypertension suggests water excess, and thus appropriate 
treatment would be fluid restriction, yet this will limit caloric intake in babies. An expert 
consensus statement on ARPKD acknowledged this dilemma, but stated that it was unclear 
whether the water excess was due to excess arginine vasopressin (AVP) or tubule-interstitial 
dysfunction [8]. And this is, where the case provides some tantalizing information: At 1-month 
of age, because of the hyponatremia and difficult clinical situation, the infant commenced 
treatment with tolvaptan and the hyponatremia resolves. Moreover, no further growth of the 
kidneys over the following 11 months is noted, whereas the child otherwise grows normally 
and consequently the abdominal distension and associated respiratory distress also disappears. 
Unfortunately, critical pieces of information, such as osmolalities and AVP levels are not 
provided. While urine osmolality may not necessarily be informative, at least in adults with 
ADPKD [9], elevated AVP levels or its correlate co-peptin would have been helpful in 
supporting causality between tolvaptan treatment and not only the observed resolution of 
hyponatremia in this baby, but also the observed growth arrest in kidney/cyst size. The authors 
remark on increased AVP levels in PKD animals and suggest that levels could have been 
elevated in their patient due to activation of thoracic baroreceptors because of impaired cardiac 
filling with the severe abdominal distension, but this is obviously speculation. 
 
Aquaretics in neonatal PKD? 
Now, it is important to remember that this is a case report and thus no reliable evidence. It is 
possible that other groups may have tried this treatment without effect in similar cases and 
decided not to publish such “negative” results. But this case report clearly makes a point for a 
more systematic assessment of aquaretics in severe neonatal forms of PKD. Hyponatremia is 
seen in up to 25% of cases of ARPKD and hypertension is even more common. If aquaretics 
were helpful in infants with PKD and this symptom combination, this would clearly benefit 
their management and allow adequate feeding. At this point, it is completely unknown, whether 
the beneficial effect of tolvaptan on cyst growth in ADPKD can be translated to ARPKD, but 
if treatment of hyponatremia also slowed down kidney growth in these infants, that would 
obviously be a welcome “side effect”.  
 
Administering tolvaptan in babies 
Lastly, the authors report on a recipe for a suspension of tolvaptan. While the manufacturer is 
currently conducting long-term trials of tolvaptan in children, no liquid formulation suitable 
for long-term use has been provided, essentially excluding smaller children who are unable to 
take tablets from these trials. In our own off-label use, we have just crushed the tablet and 
mixed in water [10], but having a more reliable suspension available would be desirable. Let’s 
hope the manufacturer will investigate the proposed formulation for dose reliability and safety, 
as a liquid formulation obviously would facilitate treatment of infants. 
Yet, before we enthusiastically start treating hyponatremia in neonatal PKD with tolvaptan, 
perhaps, we should just start measuring co-peptin levels in these infants to see if there is 
actually any evidence of increased AVP activity which could justify the use of aquaretics. 
But, just for argument’s sake, let’s assume there was: well, which brand should we prescribe? 
SAMSCA for hyponatremia? Or JINARC for PKD? Perhaps we need a third brand with 
an intermediate price that covers both indications? “JINSCA” anyone? 
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